AnthonyW.TolcherMD

Oncology • San Antonio, TX

Breast Cancer, Sarcoma

Director of Clinical Research at START; Associate Editor of The Journal of New Anticancer Agents

Join to view full profile

Dr. Tolcher is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Tolcher's full profile

Already have an account?

Office
2829 Babcock Road
Suite 300 Tower 1
San Antonio, TX 78229
Phone+1 210-580-5900

Fax+1 210-568-4397
Is this information wrong?

Education & Training

University of British ColumbiaClass of 1986

Certifications & Licensure

TX State Medical License 1998 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 1998 Jul 01
Completed
Phase 1
Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 1998 Oct 01
Completed
Phase 1
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 1, Phase 2
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 1
Erlotinib in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2002 Jun 01
Completed
Phase 2
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 1, Phase 2
Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease Start of enrollment: 2006 Jul 01
Completed
Phase 1
Safety Study of CALAA-01 to Treat Solid Tumor Cancers Start of enrollment: 2008 May 01
Terminated
Phase 1
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors Start of enrollment: 2010 Dec 01
Completed
Phase 1
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Start of enrollment: 2013 Mar 01
Completed
Phase 1, Phase 2
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Jul 01
Terminated
Phase 1
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma Start of enrollment: 2014 Apr 01
Terminated
Phase 1
Phase 1 of EC1169 In Patients With Recurrent MCRPC Start of enrollment: 2014 May 01
Completed
Phase 1
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Start of enrollment: 2015 Sep 01
Completed
Phase 1
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors Start of enrollment: 2017 Nov 28
Active, not recruiting
Phase 1
A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer Start of enrollment: 2018 Oct 16
Completed
Phase 1
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers Start of enrollment: 2019 Apr 10
Completed
Phase 1
Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A Start of enrollment: 2019 May 01
Recruiting
Phase 1
Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2021 Jun 11
Terminated
Phase 1
Roles: Contact
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors Start of enrollment: 2022 Aug 25
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Start of enrollment: 2018 Aug 29
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
A Study of Injection HB0025 in Patients With Advanced Solid Tumors Start of enrollment: 2021 Mar 10
Recruiting
Phase 1
Roles: Contact
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) Start of enrollment: 2019 Dec 20
Active, not recruiting
Phase 1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.
Noboru Yamamoto, Iwona Lugowska, Rodryg Ramlau, Teresa Macarulla, Junxian Geng, Jian Li, Michael Teufel, Angela Märten, Anthony Tolcher, Navid Hafez, Patricia LoRusso> ;Oncotargets and Therapy. 2024 Jan 1
1 citations
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Vivek Subbiah, Sant P Chawla, Anthony P Conley, Breelyn A Wilky, Anthony Tolcher, Nehal J Lakhani, David Berz, Vasily Andrianov, William Crago, Monica Holcomb, Abrahim...> ;Clinical Cancer Research. 2023 Aug 15
5 citations
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-S...
Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, Alexander Spira, Edward B Garon, Satoru Kitazono, Melissa L Johnson, Funda Meric-Bernstam, Anthony W Tolcher, Noboru Yamamot...> ;Journal of Clinical Oncology. 2023 Oct 10
2 citations
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
Hong, D., Postow, M., Chmielowski, B., Sullivan, R., Patnaik, A., Cohen, E., Shapiro, G., Steuer, C., Gutierrez, M., Yeckes-Rodin, H., Ilaria, R., O'Connell, B., Peng,...> ;Clinical Cancer Research. 2023 Jun 13
1 citations
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Anastasios Stathis, Anthony W Tolcher, Judy S Wang, Daniel J Renouf, Lin-Chi Chen, Leah H Suttner, Tomoko Freshwater, Andrea L Webber, Tapan Nayak, Lillian L Siu> ;Investigational New Drugs. 2023 Jun 1
11 citations
The evolving landscape of antibody-drug conjugates in gynecologic cancers.
Anthony Tolcher, Erika Hamilton, Robert L Coleman> ;Cancer Treatment Reviews. 2023 May 1
10 citations
Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors.
Anthony W Tolcher, Michael Gordon, Kathleen M Mahoney, Anna Seto, Marianna Zavodovskaya, Chia-Hsiang Hsueh, Shuyan Zhai, Thomas Tarnowski, Juliane M Jürgensmeier, Susa...> ;Journal for Immunotherapy of Cancer. 2023 Feb 1
7 citations
Antibody drug conjugates: The dos and don'ts in clinical development.
Anthony W Tolcher> ;Pharmacology & Therapeutics. 2022 Dec 1
5 citations
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
Jordan Berlin, Anthony W Tolcher, Cliff Ding, Jennifer G Whisenant, Ivan D Horak, Debra L Wood, Paul I Nadler, Ulla Holm Hansen, Johan Lantto, Niels Jørgen Ø Skartved,...> ;Investigational New Drugs. 2022 Jun 1
53 citations
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
Charu Aggarwal, Amy Prawira, Scott Antonia, Osama Rahma, Anthony Tolcher, Roger B Cohen, Yanyan Lou, Ralph Hauke, Nicholas Vogelzang, Dan P Zandberg, Arash Rezazadeh K...> ;Journal for Immunotherapy of Cancer. 2022 Apr 1
11 citations
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia LoRusso, Joseph Paul Eder, Martin Gutierrez, Kumar Sankh...> ;Clinical Cancer Research. 2021 Sep 13
31 citations
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Michael L. Maitland, Jasgit C. Sachdev, Manish R. Sharma, Victor Moreno, Valentina Boni, Shivaani Kummar, Erica Stringer-Reasor, Nehal Lakhani, Allison R Moreau, Dawei...> ;Clinical Cancer Research. 2021 Aug 15
16 citations
First-in-human phase I study of ABBV-085, an antibody–drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors
George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly, Alexander I. Spira, Vivek Subbiah, Louie Naumovski, Chris Chen, Hua Fang, Dominic W. Lai, Huib...> ;Clinical Cancer Research. 2021 Apr 5
22 citations
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
Jason J. Luke, Fabrice Barlesi, Ki Y. Chung, Anthony W. Tolcher, Karen Kelly, Antoine Hollebecque, Christophe Le Tourneau, Vivek Subbiah, Frank Tsai, Steven Kao, Phili...> ;Journal for Immunotherapy of Cancer. 2021 Feb 1
5 citations
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
John D. Powderly, Alexander I. Spira, Shunsuke Kondo, Toshihiko Doi, Jason J. Luke, Drew W. Rasco, Bo Gao, Minna Tanner, Philippe A. Cassier, Anas Gazzah, Antoine Ital...> ;Clinical and Translational Science. 2021 Jan 1
30 citations
The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point.
Anthony W. Tolcher> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2020 Mar 31
13 citations
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in p...
James M. Cleary, Emiliano Calvo, Victor Moreno, Dejan Juric, Geoffrey I. Shapiro, Carol Ann Vanderwal, Beibei Hu, Maryella Gifford, David, Lisa Roberts-Rapp, Peter Ans...> ;Investigational New Drugs. 2020 Mar 18
34 citations
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors
Lee S. Rosen, Robert Wesolowski, Raffaele Baffa, Kai-Hsin Liao, Steven Y. Hua, Brenda Gibson, Steven Pirie-Shepherd, Anthony W. Tolcher> ;Investigational New Drugs. 2020 Feb 1
21 citations
A Phase 1 Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults With Advanced Cancers or Lymphoma.
Monica M. Mita, Patricia LoRusso, Kyriakos P. Papadopoulos, Michael S. Gordon, Alain C. Mita, Roberta Ferraldeschi, Harold N. Keer, Aram Oganesian, Xiang Yao Su, Simon...> ;Clinical Cancer Research. 2020 Jan 3
47 citations
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
David Smith, Rashmi Chugh, Amita Patnaik, Kyriakos P. Papadopoulos, Min Wang, Ann M. Kapoun, Lu Xu, Jakob Dupont, Robert Joseph Stagg, Anthony W. Tolcher> ;Investigational New Drugs. 2019 Aug 1
2OA phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors.
Tolcher, A. W.,Fang, D. D.,Li, Y.,Tang, Y.,Ji, J.,Wang, H.,Karim, R.,Rosas, C.,Huang, Y.,Zhai, Y.> ;Ann. Oncol.. 2019 Feb 28
10 citations
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer
Jonathan W. Goldman, Lee S. Rosen, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Peipei Shi, Celine Pitou, Robert Bell, Palaniappan Kulanthaivel, Xu...> ;Investigational New Drugs. 2018 Aug 1
38 citations
A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
Anthony W. Tolcher, Keith T. Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas E. Witzig, Thomas M. Habermann, Andrea J. Bullock, Edwin P. Rock, Agnes Elekes, Chest...> ;The Oncologist. 2018 Jun 1
41 citations
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Glenwood D. Goss, Everett E. Vokes, Michael S. Gordon, Leena Gandhi, Kyriakos P. Papadopoulos, Drew W. Rasco, JuDee Fischer, Katharine L. Chu, William Ames, Rajendar K...> ;Cancer. 2018 May 15
53 citations
Improving combination cancer therapy: the CombiPlex® development platform.
Anthony W. Tolcher, Lawrence D. Mayer> ;Future Oncology. 2018 Jan 24
Join now to see all

Lectures

Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
2019 ASCO Annual Meeting - 6/1/2019
An open label, multicenter, phase 1b/2 study of rebastinib (DCCâ€‘2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patient...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Vial, Working with Top Phase I Oncology SitesApril 19th, 2023
Weekly Quick Hits (Greater Philadelphia) – Week of February 6, 2023February 9th, 2023
Teon Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate TT-816, a Novel Oral Immune Response Modifier, in Combination with KEYTRUDA® (Pembrolizumab)January 18th, 2023
Join now to see all

Grant Support

PH I Study Of EGFR And HER2 Blockade W/ OSI-774, Trastuzumab And PaclitaxelNational Center For Research Resources2006–2007
Phase I Clinical Trials Of Anti-Cancer AgentsNational Cancer Institute2004–2006
PH II PK And Biologic Correlative Study Of OSI-774 In PTS W/ Adv Renal Cell CarcNational Center For Research Resources2005
PH I Study Of EGFR And HER2 Blockade W OSI-774, Trastuzumab And PaclitaxelNational Center For Research Resources2005
Phase I/II Study Of Oblimersen Sodium With LeucovorinNational Center For Research Resources2004
PH II Pharmakokinetic/Biologic Study Of OSI-774 In RCCNational Center For Research Resources2004
Trial Of RPR 116258a--1 HR IV Infusion In Solid TumorsNational Center For Research Resources2000–2002
Pharmacokinetics/Safety Of INGN 201 In Advanced TumorsNational Center For Research Resources2000–2002
Pharmacokinetics Of Sr45023a 7 Day Administration CycleNational Center For Research Resources2000–2002
Pharmacokinetics Of FB 642 In Patients With Advanced TumNational Center For Research Resources2000–2002
Phase I Study Of Cyclic Oral Administration Of Sch61365 (21 Of 28 Days)National Center For Research Resources1999–2002

Hospital Affiliations

Methodist HospitalSan Antonio, Texas
CHRISTUS Santa Rosa Hospital - New BraunfelsNew Braunfels, Texas